Document:

Exhibit

Exhibit 10.84

INDEMNIFICATION AGREEMENT

THIS INDEMNIFICATION AGREEMENT (“Agreement”) is made and entered into as of the 15th day of December, 2014, by and between Hudson Pacific Properties, Inc., a Maryland corporation (the “Company”), and Robert L. Harris II (“Indemnitee”).
WHEREAS, at the request of the Company, Indemnitee currently serves as a director of the Company and may, therefore, be subjected to claims, suits or proceedings arising as a result of his service; and
WHEREAS, as an inducement to Indemnitee to continue to serve as such director, the Company has agreed to indemnify and to advance expenses and costs incurred by Indemnitee in connection with any such claims, suits or proceedings, to the maximum extent permitted by law; and
WHEREAS, the parties by this Agreement desire to set forth their agreement regarding indemnification and advance of expenses;
NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:
Section 1.Definitions.  For purposes of this Agreement:
(a)    “Adjudged” shall mean adjudged finally by a court or arbitral or other authority of competent jurisdiction.
(b)    “Change in Control” means a change in control of the Company occurring after the Effective Date of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or in response to any similar item on any similar schedule or form) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), whether or not the Company is then subject to such reporting requirement; provided, however, that, without limitation, such a Change in Control shall be deemed to have occurred if, after the Effective Date (i) any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) is or becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing 50% or more of the combined voting power of all of the Company’s then-outstanding securities entitled to vote generally in the election of directors without the prior approval of at least two-thirds of the members of the Board of Directors in office immediately prior to such person’s attaining such percentage interest; (ii) the Company is a party to a merger, consolidation, sale of assets, plan of liquidation or other reorganization not approved by at least two-thirds of the members of the 

-1-

Exhibit 10.84

Board of Directors then in office, as a consequence of which members of the Board of Directors in office immediately prior to such transaction or event constitute less than a majority of the Board of Directors thereafter; or (iii) at any time, a majority of the members of the Board of Directors are not comprised of (A) individuals who were directors as of the Effective Date and/or (B) individuals whose election by the Board of Directors or nomination for election by the Company’s stockholders was approved by the affirmative vote of at least two-thirds of the directors then in office who were directors as of the Effective Date or whose election for nomination for election was previously so approved.
(c)    “Corporate Status” means the status of a person as a present or former director, officer, employee or agent of the Company or as a director, trustee, officer, partner, manager, managing member, fiduciary, employee or agent of any Enterprise.  
(d)    “Disinterested Director” means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification and/or advance of Expenses is sought by Indemnitee.
(e)    “Effective Date” means the date set forth in the first paragraph of this Agreement.
(f)    “Enterprise” means any foreign or domestic corporation, partnership, limited liability company, joint venture, trust, employee benefit plan or other enterprise in which Indemnitee is or was serving as a director, trustee, officer, partner, manager, managing member, fiduciary, employee or agent at the request of the Company.  As a clarification and without limiting the circumstances in which Indemnitee may be serving at the request of the Company, service by Indemnitee shall be deemed to be at the request of the Company if Indemnitee serves or served as a director, trustee, officer, partner, manager, managing member, fiduciary, employee or agent of any corporation, partnership, limited liability company, joint venture, trust, employee benefit plan or other enterprise (i) of which a majority of the voting power or equity interest is owned directly or indirectly by the Company or (ii) the management of which is controlled directly or indirectly by the Company.
(g)    “Expenses” means any and all disbursements or expenses incurred by Indemnitee in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in or otherwise participating in a Proceeding, including, without limitation, reasonable attorneys’ fees and costs, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, and any ERISA excise taxes and penalties.  Expenses shall also include (i) expenses incurred in connection with any appeal resulting from any Proceeding including, without limitation, the 

-2-

Exhibit 10.84

premium, security for and other costs relating to any cost bond, supersedeas bond or other appeal bond or its equivalent, (ii) expenses incurred in connection with recovery under any directors’ and officers’ liability insurance policies maintained by the Company, regardless of whether the Indemnitee is ultimately determined to be entitled to such indemnification, advancement or expenses or insurance recovery, as the case may be, and (iii) expenses incurred by Indemnitee in establishing or enforcing his right to indemnification or reimbursement under this Agreement.  Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments, fines or penalties against Indemnitee (other than ERISA excise tax penalties). 
(h)    “Independent Counsel” means a law firm, or a member of a law firm, that is of outstanding reputation, experienced in matters of corporation law and neither is, nor in the past five years preceding the date of selection has been, retained to represent:  (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning Indemnitee under this Agreement or of other indemnitees under similar indemnification agreements), or (ii) any other party to or participant or witness in the Proceeding giving rise to a claim for indemnification or advance of Expenses hereunder.  Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement.  The Company agrees to pay the reasonable fees and expenses of the Independent Counsel.
(i)    “Proceeding” means any threatened, pending or completed action, suit, arbitration, mediation, alternate dispute resolution procedure, investigation, inquiry, administrative hearing or any other proceeding, whether brought by or in the right of the Company or otherwise and whether of a civil (including intentional or unintentional tort claims), criminal, administrative or investigative (formal or informal) nature, including any appeal therefrom, in which Indemnitee was, is, will or might be involved as a party or otherwise, by reason of any action taken by or omission by Indemnitee, or of any action or omission on Indemnitee’s part, in each case in or in connection with Indemnitee’s Corporate Status and whether or not acting or serving in such capacity at the time any liability or Expense is incurred for which indemnification, reimbursement or advancement of Expenses can be provided under this Agreement, except one pending or completed on or before the Effective Date, unless otherwise specifically agreed in writing by the Company and Indemnitee.  If Indemnitee reasonably believes that a given situation may lead to or culminate in the institution of a Proceeding, such situation shall also be considered a Proceeding.  The term “Proceeding” shall be broadly construed and shall include, without limitation, the investigation, preparation, prosecution, defense, settlement, arbitration or appeal of, and the giving of testimony in or 

-3-

Exhibit 10.84

related to, any threatened, pending or completed claim, action, suit or other proceeding, whether of a civil, criminal, administrative or investigative nature.
Section 2.    Services by Indemnitee.  The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce the Indemnitee to serve or continue to serve as a director of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving or continuing to serve as a director.  However, this Agreement shall not impose any independent obligation on Indemnitee or the Company to continue Indemnitee’s service to the Company.  This Agreement shall not be deemed an employment contract between the Company (or any other entity) and Indemnitee.
Section 3.    General.  The Company shall indemnify, hold harmless and exonerate, and advance Expenses to, Indemnitee (a) as provided in this Agreement and (b) otherwise to the maximum extent not prohibited by (and not merely to the extent affirmatively permitted by) Maryland law in effect on the Effective Date and as amended from time to time; provided, however, that no change in Maryland law shall have the effect of reducing the benefits available to Indemnitee hereunder based on Maryland law as in effect on the Effective Date.  The rights of Indemnitee provided in this Section 3 shall include, without limitation, the rights set forth in the other sections of this Agreement, including any additional indemnification permitted by Section 2-418(g) of the Maryland General Corporation Law (the “MGCL”).
Section 4.    Indemnification.  If Indemnitee is, or is threatened to be, made a party to any Proceeding, the Company shall indemnify, hold harmless and exonerate Indemnitee against all judgments, penalties, fines and amounts paid in settlement and all Expenses actually and reasonably incurred by him or on his behalf in connection with any such Proceeding unless (and only to the extent) it is established that (a) the act or omission of Indemnitee was material to the matter giving rise to the Proceeding and (i) was committed in bad faith or (ii) was the result of active and deliberate dishonesty, (b) Indemnitee actually received an improper personal benefit in money, property or services or (c) in the case of any criminal Proceeding, Indemnitee had reasonable cause to believe that the act or omission was unlawful.
Section 5.    Certain Limits on Indemnification.  Notwithstanding any other provision of this Agreement (other than Section 6), Indemnitee shall not be entitled to:
(a)    indemnification hereunder if the Proceeding was one by or in the right of the Company and Indemnitee is Adjudged to be liable to the Company; 
(b)    indemnification hereunder if Indemnitee is Adjudged to be liable on the basis that personal benefit was improperly received in any Proceeding charging improper personal benefit to Indemnitee; or

-4-

Exhibit 10.84

(c)    indemnification or advance of Expenses hereunder if the Proceeding was brought by Indemnitee unless: (i) the Proceeding was brought to establish or enforce indemnification rights under this Agreement, and then only to the extent in accordance with and as authorized by Section 12 of this Agreement, or (ii) the Company’s charter or Bylaws, a resolution of the stockholders entitled to vote generally in the election of directors or of the Board of Directors or an agreement approved by the Board of Directors to which the Company is a party expressly provide otherwise.
Section 6.    Court-Ordered Indemnification.  Notwithstanding any other provision of this Agreement, a court of appropriate jurisdiction, upon application of Indemnitee and such notice as the court shall require, may order indemnification in the following circumstances:
(a)    if it determines Indemnitee is entitled to reimbursement under Section 2-418(d)(1) of the MGCL, the court shall order indemnification, in which case Indemnitee shall be entitled to recover the Expenses of securing such reimbursement; or
(b)    if it determines that Indemnitee is fairly and reasonably entitled to indemnification in view of all the relevant circumstances, whether or not Indemnitee (i) has met the standards of conduct set forth in Section 2-418(b) of the MGCL or (ii) has been Adjudged liable for receipt of an improper personal benefit under Section 2-418(c) of the MGCL, the court may order such indemnification as the court shall deem proper.  However, indemnification with respect to any Proceeding by or in the right of the Company or in which liability shall have been Adjudged in the circumstances described in Section 2-418(c) of the MGCL shall be limited to Expenses.
Section 7.    Indemnification for Expenses of a Party Who is Wholly or Partly Successful.  Notwithstanding any other provision of this Agreement, and without limiting any such provision, to the extent that Indemnitee was or is made a party to (or otherwise becomes a participant in) any Proceeding and is successful, on the merits or otherwise, in the defense of such Proceeding, Indemnitee shall be indemnified for all Expenses actually and reasonably incurred by him or on his behalf in connection therewith.  If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee under this Section 7 for all Expenses actually and reasonably incurred by him or on his behalf in connection with each such claim, issue or matter, allocated on a reasonable and proportionate basis.  For purposes of this Section 7 and, without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.

-5-

Exhibit 10.84

Section 8.    Advance of Expenses for a Party.  If Indemnitee was, is, or is threatened to be, made a party to any Proceeding, the Company shall, without requiring a preliminary determination of Indemnitee’s ultimate entitlement to indemnification hereunder, advance all reasonable Expenses incurred by or on behalf of Indemnitee in connection with such Proceeding within ten days after the receipt by the Company of a statement or statements requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding.  Such statement or statements shall reasonably evidence the Expenses incurred by Indemnitee and shall include or be preceded or accompanied by a written affirmation by Indemnitee of Indemnitee’s good faith belief that the standard of conduct necessary for indemnification by the Company as authorized by law and by this Agreement has been met and a written undertaking by or on behalf of Indemnitee, in substantially the form attached hereto as Exhibit A or in such form as may be required under applicable law as in effect at the time of the execution thereof, to reimburse the portion (if any) of any Expenses advanced to Indemnitee relating to claims, issues or matters in the Proceeding as to which it shall ultimately be established that the standard of conduct has not been met by Indemnitee and which have not been successfully resolved as described in Section 7 of this Agreement.  Advances shall be interest-free and unsecured.  The undertaking required by this Section 8 shall be an unlimited general obligation by or on behalf of Indemnitee and shall be accepted without reference to Indemnitee’s financial ability to repay such advanced Expenses and without any requirement to post security therefor.
Section 9.    Indemnification and Advance of Expenses of a Witness.  Notwithstanding any other provision of this Agreement, to the extent that Indemnitee was, is or may be made a witness or otherwise asked to participate in any Proceeding, whether instituted by the Company or any other party, and to which Indemnitee is not a party, he shall be advanced all reasonable Expenses and indemnified, held harmless and exonerated against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith within ten days after the receipt by the Company of a statement or statements requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding.  Such statement or statements shall reasonably evidence the Expenses incurred by Indemnitee.  Advances shall be interest-free and unsecured.
Section 10.    Procedure for Determination of Entitlement to Indemnification.
(a)    To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification.  Indemnitee may submit one or more such requests from time to time and at such time(s) as Indemnitee deems appropriate in his sole discretion.  The officer of the Company receiving any such request from Indemnitee shall, 

-6-

Exhibit 10.84

promptly upon receipt of such a request for indemnification, advise the Board of Directors in writing that Indemnitee has requested indemnification.
(b)    Upon written request by Indemnitee for indemnification pursuant to Section 10(a) above, a determination, if required by applicable law, with respect to Indemnitee’s entitlement thereto shall promptly be made in the specific case: (i) if a Change in Control shall have occurred, by Independent Counsel, in a written opinion to the Board of Directors, a copy of which shall be delivered to Indemnitee, which Independent Counsel shall be selected by the Indemnitee and approved by the Board of Directors in accordance with Section 2-418(e)(2)(ii) of the MGCL, which approval will not be unreasonably withheld; or (ii) if a Change in Control shall not have occurred, (A) by the Board of Directors by a majority vote of a quorum consisting entirely of Disinterested Directors or, if such a quorum cannot be obtained, then by a majority vote of a duly authorized committee of the Board of Directors consisting solely of one or more Disinterested Directors, (B) if Independent Counsel has been selected by the Board of Directors in accordance with Section 2-418(e)(2)(ii) of the MGCL and approved by the Indemnitee, which approval shall not be unreasonably withheld, by Independent Counsel, in a written opinion to the Board of Directors, a copy of which shall be delivered to Indemnitee or (C) if so directed by a majority of the members of the Board of Directors, by the stockholders of the Company.  If it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten days after such determination.  Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination in the discretion of the Board of Directors or Independent Counsel if retained pursuant to clause (ii)(B) of this Section 10(b).  Any Expenses incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification) and the Company shall indemnify and hold Indemnitee harmless therefrom.
(c)    The Company shall pay the reasonable fees and expenses of Independent Counsel, if one is appointed.
Section 11.    Presumptions and Effect of Certain Proceedings.
(a)    In making any determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination shall presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 10(a) of this Agreement, and the Company shall have the burden of proof and the burden of persuasion by clear and convincing 

-7-

Exhibit 10.84

evidence to overcome that presumption in connection with the making of any determination contrary to that presumption.  
(b)    The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, upon a plea of nolo contendere or its equivalent, or entry of an order of probation prior to judgment, does not create a presumption that Indemnitee did not meet the requisite standard of conduct described herein for indemnification.
(c)    The knowledge and/or actions, or failure to act, of any other director, officer, employee or agent of the Company or any other director, trustee, officer, partner, manager, managing member, fiduciary, employee or agent of any Enterprise shall not be imputed to Indemnitee for purposes of determining any other right to indemnification under this Agreement.
(d)    For purposes of any determination as to Indemnitee’s entitlement of indemnification, Indemnitee shall be presumed to have met the standard of conduct for indemnification if, among other things and without limitation, Indemnitee relied on any information, opinion, report or statement, including any financial statement or other financial data or the records or books of account of the Company or any other Enterprise, prepared or presented by an officer or employee of the Company or any Enterprise whom Indemnitee reasonably believed to be reliable and competent in the matters presented, by a lawyer, certified public accountant, appraiser or other person or expert, as to a matter which Indemnitee reasonably believed to be within the person’s professional or expert competence, or, if Indemnitee was serving on the Board of Directors of the Company or as a member of any similar body of any Enterprise, by a committee of the Board of Directors or such other body on which Indemnitee does not serve, as to a matter within its designated authority, if Indemnitee reasonably believes the committee to merit confidence.  The provisions of this Section 11(d) shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee meet, or be presumed to have met, the applicable standard of conduct set forth in this Agreement.  
(e)    For purposes of  this Agreement, Indemnitee shall be considered to have been wholly successful with respect to any Proceeding if such Proceeding is disposed of, on the merits or otherwise (including a disposition without prejudice), without (i) the disposition being adverse to Indemnitee, (ii) it being Adjudged that Indemnitee was liable to the Company, (iii) a plea of guilty by Indemnitee, (iv) it being Adjudged that an act or omission of Indemnitee was material to the matter giving rise to the Proceeding and was (A) committed in bad faith or (B) the result of Indemnitee’s active and deliberate dishonesty, (v) it being Adjudged that Indemnitee actually received an improper personal benefit in money, property or services or (vi) with respect to any criminal proceeding, it being Adjudged that Indemnitee had reasonable cause to believe the act or omission was unlawful.

-8-

Exhibit 10.84

Section 12.    Remedies of Indemnitee.
(a)    If (i) a determination is made pursuant to Section 10(b) of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advance of Expenses is not timely made pursuant to Section 8 or Section 9 of this Agreement, (iii) no determination of entitlement to indemnification shall have been made pursuant to Section 10(b) of this Agreement within 60 days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to Section 7 of this Agreement within ten days after receipt by the Company of a written request therefor, or (v) payment of indemnification pursuant to any other section of this Agreement or the charter or Bylaws of the Company is not made within ten days after a determination has been made that Indemnitee is entitled to indemnification, Indemnitee shall be entitled to an adjudication in an appropriate court located in the State of Maryland, or in any other court of competent jurisdiction, of his entitlement to such indemnification or advance of Expenses.  Alternatively, Indemnitee, at his option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association.  Indemnitee shall commence a proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 12(a); provided, however, that the foregoing clause shall not apply to a proceeding brought by Indemnitee to enforce his rights under Section 7 of this Agreement.  Except as set forth herein, the provisions of Maryland law (without regard to its conflicts of laws rules) shall apply to any such arbitration.  The Company shall not oppose Indemnitee’s right to seek any such adjudication or award in arbitration.  
(b)    In any judicial proceeding or arbitration commenced pursuant to this Section 12, Indemnitee shall be presumed to be entitled to indemnification or advance of Expenses, as the case may be, under this Agreement and the Company shall have the burden of proving that Indemnitee is not entitled to indemnification or advance of Expenses, as the case may be.  If Indemnitee commences a judicial proceeding or arbitration pursuant to this Section 12, Indemnitee shall not be required to reimburse the Company for any advances pursuant to Section 8 of this Agreement until a final determination is made with respect to Indemnitee’s entitlement to indemnification (as to which all rights of appeal have been exhausted or lapsed).  If Indemnitee commences a judicial proceeding or arbitration pursuant to this Section 12, the Company may not refer to or introduce into evidence any determination pursuant to Section 10(b) of this Agreement adverse to Indemnitee for any purpose and any judicial proceeding or arbitration commenced pursuant to this Article 12 shall be conducted in all respects as a de novo trial or arbitration.  The Company shall, to the fullest extent not prohibited by law, be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 12 that the procedures and presumptions of this Agreement are not valid, binding and enforceable 

-9-

Exhibit 10.84

and shall stipulate in any such court or before any such arbitrator that the Company is bound by all of the provisions of this Agreement.
(c)    If a determination shall have been made pursuant to Section 10(b) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 12, absent a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification.
(d)    In the event that Indemnitee, pursuant to this Section 12, seeks a judicial adjudication of or an award in arbitration to enforce his rights under, or to recover damages for breach of, this Agreement, Indemnitee shall be entitled to advancement from the Company, and shall be indemnified and held harmless by the Company for, any and all Expenses actually and reasonably incurred by him in such judicial adjudication or arbitration in accordance with this Agreement.  
(e)    Interest shall be paid by the Company to Indemnitee at the maximum rate allowed to be charged for judgments under the Courts and Judicial Proceedings Article of the Annotated Code of Maryland for amounts which the Company pays or is obligated to pay for the period commencing with the date on which the Indemnitee requests indemnification or advancement of Expenses in accordance with this Agreement and ending on the date such payment is made to Indemnitee by the Company.
Section 13.    Defense of the Underlying Proceeding.
(a)    Indemnitee shall notify the Company promptly in writing upon being served with any summons, citation, subpoena, complaint, indictment, request or other document relating to any Proceeding which may result in the right to indemnification or the advance of Expenses hereunder and shall include with such notice a description of the nature of the Proceeding and a summary of the facts underlying the Proceeding.  The failure to give any such notice shall not disqualify Indemnitee from the right, or otherwise affect in any manner any right of Indemnitee, to indemnification or the advance of Expenses under this Agreement unless the Company’s ability to defend in such Proceeding or to obtain proceeds under any insurance policy is materially and adversely prejudiced thereby, and then only to the extent the Company is thereby actually so prejudiced.
(b)    Subject to the provisions of the last sentence of this Section 13(b) and of Section 13(c) below, the Company shall have the right to defend Indemnitee in any Proceeding which may give rise to indemnification hereunder using a law firm of the Company’s choice, subject to the prior written approval of the Indemnitee, which shall not be unreasonably withheld; 

-10-

Exhibit 10.84

provided, however, that the Company shall notify Indemnitee in writing of any such decision to defend within 15 calendar days following receipt of notice of any such Proceeding under Section 13(a) above.  Indemnitee shall have the right to retain a separate law firm in any such Proceeding at Indemnitee’s sole expense.  The Company shall not, without the prior written consent of Indemnitee, which shall not be unreasonably withheld or delayed, consent to the entry of any judgment against Indemnitee or enter into any settlement or compromise which (i) includes an admission of fault of Indemnitee, (ii) does not include, as an unconditional term thereof, the full release of Indemnitee from all liability in respect of such Proceeding, which release shall be in form and substance reasonably satisfactory to Indemnitee or (iii) would impose any Expense, judgment, fine, penalty or limitation on Indemnitee.  This Section 13(b) shall not apply to a Proceeding brought by Indemnitee under Section 12 of this Agreement, a Proceeding by or in the right of the Company or in the case of clause (ii) of Section 13(c).
(c)    Notwithstanding the provisions of Section 13(b) above, if in a Proceeding to which Indemnitee is a party (i) Indemnitee reasonably concludes, based upon an opinion of counsel approved by the Company, which approval shall not be unreasonably withheld, that he may have separate defenses or counterclaims to assert with respect to any issue which may not be consistent with other defendants in such Proceeding, (ii) Indemnitee reasonably concludes that an actual or apparent conflict of interest or potential conflict of interest exists between Indemnitee and the Company, or (iii) if the Company fails to assume the defense of such Proceeding in a timely manner, Indemnitee shall be entitled to be represented by separate legal counsel of Indemnitee’s choice, subject, except in the case of (ii) or (iii) above, to the prior approval of the Company, which shall not be unreasonably withheld, at the expense of the Company.  In addition, if the Company fails to comply with any of its obligations under this Agreement or in the event that the Company or any other person takes any action to declare this Agreement void or unenforceable, or institutes any Proceeding to deny or to recover from Indemnitee the benefits intended to be provided to Indemnitee hereunder, Indemnitee shall have the right to retain counsel of Indemnitee’s choice, at the expense of the Company (subject to Section 12(d) of this Agreement), to represent Indemnitee in connection with any such matter.
Section 14.    Jointly Indemnifiable Claims.
(a)    Given that certain Jointly Indemnifiable Claims may arise, the Company acknowledges and agrees that the Company shall, and to the extent applicable shall cause any Enterprise to (i) be fully and primarily responsible for, and be the indemnitor of first resort with respect to, payment to or payment on behalf of the Indemnitee in respect of indemnification or advancement of Expenses in connection with any such Jointly Indemnifiable Claim, irrespective of any right of recovery the Indemnitee may have from the Third-Party Indemnitors, and (ii) be required to advance the full amount of Expenses incurred by the Indemnitee and shall be liable for the full amount of all Expenses, judgments, fines, penalties and amounts paid in settlement to 

-11-

Exhibit 10.84

the extent not prohibited by (and not merely to the extent affirmatively permitted by) applicable law and as required by the terms of this Agreement, without regard to any rights the Indemnitee may have against the Third-Party Indemnitors.  Under no circumstance shall the Company or any Enterprise be entitled to, and the Company hereby irrevocably waives, relinquishes and releases, any claims against the Third-Party Indemnitors for subrogation, contribution or recovery of any kind and no right of advancement or recovery the Indemnitee may have from the Third-Party Indemnitors shall reduce or otherwise alter the rights of the Indemnitee or the obligations of the Company or any Enterprise.  The Company further agrees that no advancement or payment by any Third-Party Indemnitor on behalf of Indemnitee with respect to any Proceeding for which Indemnitee has sought indemnification, exoneration or hold harmless rights from the Company shall affect the foregoing and the Third-Party Indemnitor(s) shall have a right to receive from the Company, contribution and/or be subrogated, to the extent of such advancement or payment to all of the rights of recovery of Indemnitee against the Company.  The Company and the Indemnitee agree that each of the Third-Party Indemnitors shall be third-party beneficiaries with respect to this Agreement entitled to enforce this Section 14 as though each such Third-Party Indemnitor were a party to this Agreement.
(b)    For purposes of this Agreement “Third-Party Indemnitor” means any person or entity that has or may in the future provide to the Indemnitee any indemnification, exoneration, hold harmless or Expense advancement rights and/or insurance benefits other than (i) the Company, (ii) any Enterprise and (iii) any entity or entities through which the Company maintains liability insurance applicable to the Indemnitee.
(c)    For purposes of this Agreement, “Jointly Indemnifiable Claims” shall mean any Proceeding for which the Indemnitee shall be entitled to indemnification, advancement of expenses or insurance from (i) the Company and/or any Enterprise pursuant to this Agreement, the charter or Bylaws or other governing documents of the Company or any Enterprise, any agreement or a resolution of the stockholders of the Company entitled to vote generally in the election of directors or of the Board of Directors, or otherwise, on the one hand, and (ii) any Third-Party Indemnitor pursuant to any agreement between any Third-Party Indemnitor and the Indemnitee pursuant to which the Indemnitee is indemnified, the laws of the jurisdiction of incorporation or organization of any Third-Party Indemnitor and/or the certificate of incorporation, certificate of organization, bylaws, partnership agreement, operating agreement, certificate of formation, certificate of limited partnership or other organizational or governing documents of any Third-Party Indemnitor, on the other hand.
Section 15.    Non-Exclusivity; Survival of Rights; Subrogation.
(a)    The rights of indemnification and advance of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any 

-12-

Exhibit 10.84

time be entitled under applicable law, the charter or Bylaws or other governing documents of the Company or any Enterprise, any agreement or a resolution of the stockholders entitled to vote generally in the election of directors or of the Board of Directors, or otherwise.  Unless consented to in writing by Indemnitee, no amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in or by reason of his Corporate Status prior to such amendment, alteration or repeal, regardless of whether a claim with respect to such action or inaction is raised prior or subsequent to such amendment, alteration or repeal.  No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right or remedy shall be cumulative and in addition to every other right or remedy given hereunder or now or hereafter existing at law or in equity or otherwise.  The assertion of any right or remedy hereunder, or otherwise, shall not prohibit the concurrent assertion or employment of any other right or remedy.
(b)    Except as set forth in Section 14, in the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.
Section 16.    Insurance.  The Company will use its reasonable best efforts to acquire directors and officers liability insurance, on terms and conditions deemed appropriate by the Board of Directors, with the advice of counsel, covering Indemnitee or any claim made against Indemnitee by reason of his Corporate Status or by reason of alleged actions or omissions by Indemnitee in such capacity and covering the Company for any indemnification or advance of Expenses made by the Company to Indemnitee for any claims made against Indemnitee by reason of his Corporate Status or by reason of alleged actions or omissions by Indemnitee in such capacity.  Without in any way limiting any other obligation under this Agreement, the Company shall indemnify Indemnitee for any payment by Indemnitee arising out of the amount of any deductible or retention and the amount of any excess of the aggregate of all judgments, penalties, fines, settlements and Expenses incurred by Indemnitee in connection with a Proceeding over the coverage of any insurance referred to in the previous sentence.  The purchase, establishment and maintenance of any such insurance shall not in any way limit or affect the rights or obligations of the Company or Indemnitee under this Agreement except as expressly provided herein, and the execution and delivery of this Agreement by the Company and the Indemnitee shall not in any way limit or affect the rights or obligations of the Company under any such insurance policies.  If, at the time the Company receives notice from any source of a Proceeding to which Indemnitee is a party or a participant (as a witness or otherwise) the Company has director and officer liability insurance in effect, the Company shall give prompt notice of such Proceeding to the insurers in accordance with the procedures set forth in the respective policies.

-13-

Exhibit 10.84

Section 17.    Coordination of Payments.  Except as set forth in Section 14, the Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable or payable or reimbursable as Expenses hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.
Section 18.    Reports to Stockholders.  To the extent required by the MGCL, the Company shall report in writing to its stockholders the payment of any amounts for indemnification of, or advance of Expenses to, Indemnitee under this Agreement arising out of a Proceeding by or in the right of the Company with the notice of the meeting of stockholders of the Company next following the date of the payment of any such indemnification or advance of Expenses or prior to such meeting.
Section 19.    Duration of Agreement; Binding Effect.
(a)    This Agreement shall be effective as of the Effective Date and may apply to acts or omissions of Indemnitee taken in or in connection with Indemnitee’s Corporate Status which occurred prior to such date if Indemnitee was an officer, director, employee or agent of the Company or was a director, trustee, officer, partner, manager, managing member, fiduciary, employee or agent of any Enterprise at the time such act or omission occurred.
(b)    This Agreement shall continue until and terminate on the later of (i) the date that Indemnitee shall have ceased to serve as a director, officer, employee or agent of the Company or as a director, trustee, officer, partner, manager, managing member, fiduciary, employee or agent of any Enterprise and (ii) the date that Indemnitee is no longer subject to any actual or possible Proceeding (including any rights of appeal thereto and any Proceeding commenced by Indemnitee pursuant to Section 12 of this Agreement).  
(c)    The indemnification and advance of Expenses provided by, or granted pursuant to, this Agreement shall be binding upon and be enforceable by the parties hereto and their respective successors and assigns (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), shall continue as to an Indemnitee who has ceased to be a director, officer, employee or agent of the Company or a director, trustee, officer, partner, manager, managing member, fiduciary, employee or agent of any Enterprise, and shall inure to the benefit of Indemnitee and his spouse, assigns, heirs, devisees, executors and administrators and other legal representatives.
(d)    The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all, substantially all or a substantial part, of the business and/or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and 

-14-

Exhibit 10.84

to the same extent that the Company would be required to perform if no such succession had taken place.
(e)    The Company and Indemnitee agree herein that a monetary remedy for breach of this Agreement, at some later date, may be inadequate, impracticable and difficult of proof, and further agree that such breach may cause Indemnitee irreparable harm.  Accordingly, the parties hereto agree that Indemnitee may enforce this Agreement by seeking injunctive relief and/or specific performance hereof, without any necessity of showing actual damage or irreparable harm and that by seeking injunctive relief and/or specific performance, Indemnitee shall not be precluded from seeking or obtaining any other relief to which he may be entitled.  Indemnitee shall further be entitled to such specific performance and injunctive relief, including temporary restraining orders, preliminary injunctions and permanent injunctions, without the necessity of posting bonds or other undertakings in connection therewith.  The Company acknowledges that, in the absence of a waiver, a bond or undertaking may be required of Indemnitee by a court, and the Company hereby waives any such requirement of such a bond or undertaking.
Section 20.    Section 409A.  It is intended that any indemnification payment or advancement of Expenses made hereunder shall be exempt from Section 409A of the Internal Revenue Code of 1986, as amended, and the guidance issued thereunder (“Section 409A”) pursuant to Treasury Regulation Section 1.409A-1(b)(10).  Notwithstanding the foregoing, if any indemnification payment or advancement of Expenses made hereunder shall be determined to be “nonqualified deferred compensation” within the meaning of Section 409A, then (i) the amount of the indemnification payment or advancement of Expenses during one taxable year shall not affect the amount of the indemnification payments or advancement of Expenses during any other taxable year, (ii) the indemnification payments or advancement of Expenses must be made on or before the last day of the Indemnitee’s taxable year following the year in which the expense was incurred, and (iii) the right to indemnification payments or advancement of Expenses hereunder is not subject to liquidation or exchange for another benefit.
Section 21.    Severability.  If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any Section, paragraph or sentence of this Agreement containing any such provision held to be invalid, illegal or unenforceable that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any Section, paragraph or sentence of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not 

-15-

Exhibit 10.84

itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.
Section 22.    Identical Counterparts.  This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement.  One such counterpart signed by the party against whom enforceability is sought shall be sufficient to evidence the existence of this Agreement.
Section 23.    Headings.  The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.
Section 24.    Modification and Waiver.  No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by both of the parties hereto.  No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver.
Section 25.    Notices.  All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed to have been duly given if (i) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed or (ii) mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed:
(a)    If to Indemnitee, to the address set forth on the signature page hereto.
(b)    If to the Company, to:
Victor J. Coleman, Chief Executive Officer
Hudson Pacific Properties, Inc.
11601 Wilshire Blvd., Sixth Floor
Los Angeles, California 90025

or to such other address as may have been furnished in writing to Indemnitee by the Company or to the Company by Indemnitee, as the case may be.

-16-

Exhibit 10.84

Section 26.    Governing Law.  The parties agree that this Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of Maryland, without regard to its conflicts of laws rules.
Section 27.    Miscellaneous.  Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun where appropriate.

[SIGNATURE PAGE FOLLOWS]

-17-

Exhibit 10.84

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.
HUDSON PACIFIC PROPERTIES, INC.:

                        
                        

By:      /s/ Victor J. Coleman    
Name:  Victor J. Coleman
Title:  Chief Executive Officer

INDEMNITEE:

By:    /s/ Robert L. Harris
Name:  Robert L. Harris
Address:  46 Old Course Drive
Newport Beach, CA  92660

-18-

EXHIBIT A
FORM OF UNDERTAKING TO REPAY EXPENSES ADVANCED
The Board of Directors of Hudson Pacific Properties, Inc.

Re:  Undertaking to Repay Expenses Advanced

Ladies and Gentlemen:

This undertaking is being provided pursuant to that certain Indemnification Agreement dated the 15th day of December, 2014, by and between Hudson Pacific Properties, Inc., a Maryland corporation (the “Company”), and the undersigned Indemnitee (the “Indemnification Agreement”), pursuant to which I am entitled to advance of Expenses in connection with [Description of Proceeding] (the “Proceeding”).
Terms used herein and not otherwise defined shall have the meanings specified in the Indemnification Agreement.
I am subject to the Proceeding by reason of my Corporate Status or by reason of alleged actions or omissions by me in such capacity.  I hereby affirm my good belief that at all times, insofar as I was involved as a director of the Company, in any of the facts or events giving rise to the Proceeding, I (1) did not act with bad faith or active or deliberate dishonesty, (2) did not receive any improper personal benefit in money, property or services and (3) in the case of any criminal proceeding, had no reasonable cause to believe that any act or omission by me was unlawful.
In consideration of the advance of Expenses by the Company for reasonable attorneys’ fees and related Expenses incurred by me in connection with the Proceeding (the “Advanced Expenses”), I hereby agree that if, in connection with the Proceeding, it is established that (1) an act or omission by me was material to the matter giving rise to the Proceeding and (a) was committed in bad faith or (b) was the result of active and deliberate dishonesty or (2) I actually received an improper personal benefit in money, property or services or (3) in the case of any criminal proceeding, I had reasonable cause to believe that the act or omission was unlawful, then I shall promptly reimburse the portion of the Advanced Expenses relating to the claims, issues or matters in the Proceeding as to which the foregoing findings have been established.  
IN WITNESS WHEREOF, I have executed this Affirmation and Undertaking on this ___ day of ____________________, 20____.

____________________________________
Name:
Address:

-2-EX-10.1

 Exhibit 10.1 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 
  

FIAGON NA DISTRIBUTOR AGREEMENT 

AGREEMENT effective 10 August 2015 (the “Effective Date”) by and between 

Fiagon NA Corporation, a Delaware corporation, with offices at 3913 Todd Lane #101 Austin TX, 78744 (“Fiagon NA” or
“Fiagon”) 
 and 

Entellus Medical, Inc., a Delaware corporation, with offices at 3600 Holly Lane North, Suite 40, Plymouth, Minnesota 55447
(“Distributor” or “Entellus”). 
 RECITALS: 

WHEREAS, Fiagon owns the right to sell Fiagon® surgical navigation systems in
North America and to appoint distributors to implement that right; and 
 WHEREAS, Distributor is an experienced distributor of
medical products, including products which require FDA approval, and desires to begin offering Fiagon® surgical navigation systems to certain customers; and 

WHEREAS, the parties have put into writing the terms of the arrangement by which Distributor will purchase and re-sell certain Fiagon® surgical navigation systems to those certain customers in the Territory (as defined in Exhibit B). 

NOW, THEREFORE, in consideration of the above, and the terms and covenants set forth below, the parties agree as follows: 

1. Appointment of Distributor. Subject to the terms hereof: 

a. Fiagon appoints Distributor as: 

i) the exclusive distributor of the Fiagon® branded products
identified on the attached Exhibit A (the “Products”) to ENT physicians in offices, clinics, and surgery centers (excluding hospitals) located in the Territory (as defined in Exhibit B); and 

ii) the exclusive distributor solely of Fiagon GuideWires that are attached to or sold in combination and conjunction with the
Entellus balloon to hospitals in the Territory. For the sake of clarity, Fiagon retains the right to appoint other distributors to sell all Products to hospitals in the Territory except for Fiagon GuideWires that are attached to or sold in
combination and conjunction with the Entellus balloon. 

  
 1 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 The aforementioned distribution rights described in i) and ii) above are, as of the Effective
Date, subject to certain limitations due to the distribution rights of other third distributors granted by Fiagon prior to the Effective Date. Specifically, the third party distributors listed in Exhibit G may, as of the Effective Date, continue to
sell Fiagon branded products to the ENT accounts specifically mentioned in Exhibit G. Distributor agrees it will not sell Fiagon branded products into the accounts specified in Exhibit G until after [***], unless Fiagon approves in writing at an
earlier date of such sales by Distributor. 
 b. Fiagon hereby warrants that 

i) Exhibit G provides a complete list of all third party distributors that have, as of the Effective Date, the right to
distribute Fiagon branded products to ENT physicians in the offices, clinics, and surgery centers located within the Territory and that the distributors listed in Exhibit G do not, as of the Effective Date, have the right to sell Fiagon branded
products to any ENT physicians in the office, clinic or surgical center settings within the Territory other than the accounts specifically listed in Exhibit G; 

ii) it will not grant the right to such distributors to distribute (a) Products to ENT physicians in the offices, clinics,
and surgery centers or (b) Fiagon GuideWires that are attached to or sold in combination and conjunction with the Entellus balloon to hospitals, located within the Territory in any extension or renewal (including automatic renewals) of any of
the distribution agreements set forth in Exhibit G and will terminate those other distribution agreements set forth in Exhibit G that it cannot amend in accordance with this Section 1 at its first opportunity, without breaching any contracts or
otherwise engaging in any prohibited or tortious conduct; 
 iii) will not enter into any agreements with any third parties
that would allow another party to distribute (i) Products to ENT physicians in offices, clinics, or surgery centers or (ii) Fiagon GuideWires that are attached to or sold in combination and conjunction with an Entellus balloon to hospitals
located in the Territory; and 
 iv) During the Term of this Agreement, Fiagon will not collaborate with or support the
competitors of Distributor, including [***], or any company intending to develop or commercialize products that are competitive with the Products or Entellus balloon products in the Territory. For the sake of clarity, the foregoing sentence shall
not prevent Fiagon from any collaboration with or support of competitors of Distributor with regard to any products outside the Territory, or non-competitive products within the Territory. 

d. Distributor agrees not to sell Products outside the Territory unless it has first obtained the written permission of Fiagon.
Furthermore, Distributor agrees that it will 

  
 2 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
not appoint sub distributors or otherwise cause the Products to be sold in the Territory by non-employees unless it has first obtained the express written consent of Fiagon, which consent can be
granted or withheld at Fiagon’s sole discretion. Distributor shall not sell any Products to any third party if Distributor knows or reasonably believes that such third party would re-sell such Products outside the Territory, to an unauthorized
reseller, or to an unauthorized customer, however, Entellus shall have the right to sell the Products to a third-party financing company in connection with providing end-users located within the Territory with financing of Products and the Parties
understand that Entellus has no control or obligations hereunder to police the third-party financing company’s use or disposal of such Products, provided that Entellus shall instruct such third-party financing companies that it shall not sell
such Products outside the Territory. Distributor can sell to any customers within the Territory, even if those customers maintain facilities outside of the Territory, provided that the Products sold to such inter-territorial customers by Distributor
are to be consumed within the Territory. Any questions or disputes that arise with regard to which customers are within which territories, shall be submitted to, and resolved by Fiagon at its sole and complete discretion. Inquiries or purchase
requests that come to Distributor from potential customers outside its Territory shall be referred to Fiagon’s distributor in the territory in which the potential customer is located. Distributor shall adhere to the terms of any Fiagon
published distributor policies that relate to Product promotions, marketing and sales initiatives that may have impact outside of a distributor’s territory. 

2. Fiagon’s Obligations. During the Term of this Agreement, Fiagon agrees: 

a. That Fiagon will sell the Products to Distributor at Distributor Pricing (as defined below) for resale by Distributor in
accordance with the terms and conditions of this Agreement and all exhibits and attachments. The current Distributor Pricing for the Products is described in Exhibit C attached hereto. Once per contract year, Fiagon NA may modify its
Distributor Pricing by providing to Distributor no less than thirty (30) days prior written notice of that modification(s), however, Fiagon NA may not modify the pricing of any Products sold to Distributor pursuant to customer agreements under
which pricing has been previously agreed upon; 
 b. To provide, when reasonably requested by Distributor, copies of such
technical data, brochures and promotional and advertising material, as may be produced from time to time by Fiagon NA. Fiagon NA reserves the right to charge Distributor an amount not to exceed Fiagon NA’s actually incurred materials costs for
such brochures, promotional, and advertising material; 
 c. To cause Fiagon NA employees to meet from time to time with
customers and potential customers in the Territory, especially key opinion leaders, to build relationships, obtain clinical information, and support the efforts of Distributor; 

d. To forward to Distributor leads obtained by Fiagon NA of potential customers in the Territory; 

  
 3 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 e. To create a program for providing technical updates, product training,
market information, and other distributor support; 
 f. To enable Distributor to acquire, at favorable pricing or terms,
Products that will be solely used to demonstrate functionality and features to potential customers; 
 g. To provide Product
repair services to Distributor; 
 h. To address warranty issues that cannot be handled in the field by Distributor; 

i. To attend at Fiagon’s expense, from time to time, meetings, conferences, and other industry activities to try to
establish a national or regional recognition of the Products, and provide to Distributor, when possible, the opportunity to also attend such meetings, conferences and activities at Distributor’s expense; 

j. To develop and from time to time update distributor policies and procedures to deal in a dynamic fashion with situations
that arise in connection with the efforts of Fiagon NA and its distributors to effectively market and sell the Products; 

k. That Fiagon NA and Distributor will promptly communicate to each other any customer complaints or adverse events, including
those that require an MDR. Fiagon NA is required to investigate and provides a remedy to complaints and adverse events in cooperation with Entellus. Fiagon NA is responsible for filing all MDRs (medical device reports); 

l. That Fiagon NA is responsible for reporting any product recall to Distributor and will be responsible for all costs
associated with the recall; 
 m. That Fiagon NA will obtain and maintain all clearances to market the product in the
Territory including regulatory approvals; and 
 n. Throughout the term of this Agreement, including any sell-off period in
accordance with Section 8(e) hereof, obtain and maintain at its own cost and expense, from a qualified insurance company, commercial general liability insurance, for the entire Territory, naming Distributor as an additional named insured. Such
insurance policy shall include blanket contractual liability, products liability and operations liability. The amount of coverage shall be a minimum of Five Million U.S. Dollars ($5,000,000.00) (combined single limit) for each single occurrence.
Such policy or policies shall provide for thirty (30) days’ written notice to Distributor from the insurer in the event of any cancellation or termination of the policy and shall endeavor to notify Distributor in the event of a
modification of the policy. Fiagon shall, upon written request, provide Distributor with proof that such insurance is in force. 

  
 4 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 3. Distributor Obligations. Distributor hereby accepts the rights and obligations of a
Fiagon NA distributor pursuant to this Agreement and agrees that, so long as this Agreement is in effect, it will: 
 a.
Promote, demonstrate and sell Products using best efforts with a view to generating increased sale of Products pursuant to this Agreement. Distributor agrees to provide detailed sales activity reporting to Fiagon NA with the frequency and content
established in Fiagon NA’s standard dealer policies and to similarly report on Product usage and other information requested by Fiagon NA as part of its marketing efforts; 

b. Maintain well-trained and informed sales, marketing and technical personnel. Within the schedule attached as
Exhibit D, Distributor will appoint a member(s) of its staff to become the Fiagon® systems subject matter expert(s) in order to support the efforts of Distributor’s sales
personnel. Distributor will provide the resources reasonably necessary to enable its personnel to competently present and support the Products to potential customers. Until subject matter excellence is achieved by Distributor, it shall, for major
sales opportunities, be entitled to request sales assistance from Fiagon NA. Distributor will provide Fiagon NA with sufficient notice of such presentations to make necessary arrangements. Fiagon NA shall be entitled to test the specified Fiagon® subject matter experts to assess whether Distributor has complied with this obligation; 

c. Maintain a sufficient inventory of Product to ensure prompt delivery of customers when orders are placed; 

d. Deliver Products with the original unaltered labeling and logos to customers in Fiagon® packaging and with the instructions and materials provided by the manufacturer; 

e. Pay for the Products at the prices and upon the terms and conditions set forth in this Agreement (including exhibits and
attachments) or otherwise established by Fiagon NA; 
 f. Provide technical support services to purchasers of Products in the
Territory, including “first line” evaluation or treatment of warranty issues; 
 g. Make no representations or
warranties of Product performance beyond the written representations made by Fiagon in its advertising or otherwise make false or misleading representations or warranties concerning the Products; 

h. Promptly and accurately comply with all FDA and other reporting requirements relating to the experiences with use of the
Products in the fashion directed by Fiagon NA’s policies including, without limitation, reports of material malfunctions, death or disability required under 21 CFR § 803; 

i. Provide to Fiagon NA estimates of Distributor’s anticipated purchases during the up-coming quarter or year in the
manner described in Fiagon NA’s applicable policies and promptly notify Fiagon NA if Distributor anticipates a material departure from its estimates for the upcoming period(s). A failure to accurately forecast purchases shall not constitute a
breach of this Agreement but may affect the timing of delivery of Products ordered by Distributor; 

  
 5 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 j. Aspire to purchase the dollar value of Products that are prescribed in the
Performance Standards attached hereto as Exhibit E; 
 k. Comply with all laws or regulations applicable to it or
to its activity of purchasing Products from Fiagon NA and marketing and reselling Products in the Territory; 
 l. Refrain
from marketing or selling any image-guided surgery navigation system products that are substitutes for the Products or any other products that directly compete with the Products. The Parties understand that a product does not “directly
compete” with a Product if it performs the same function in a materially different way. For example, a tool used to confirm the location of a surgical instrument by endoscopic visualization or by transdermal illumination does not “directly
compete” with an IGS system that confirms the location of the instrument by computer-assisted extrapolation of the instruments position; 

m. Upon request, cooperate with Fiagon NA employees in connection with marketing, sales, and Product support initiatives of
Fiagon NA directed to customers and potential customers in the Territory; 
 n. Throughout the term of this Agreement,
including any sell-off period in accordance with Section 8(e) hereof, obtain and maintain at its own cost and expense, from a qualified insurance company, commercial general liability insurance, for the entire Territory, naming Fiagon as an
additional named insured; such insurance shall include blanket contractual liability, operations liability, advertising injury, and cross liability with an amount of coverage of at least $5,000,000 per occurrence and products liability insurance
with an amount of coverage of at least $10,000,000 per occurrence; such insurance amounts may be met via a combination of primary and umbrella policies; such policy or policies shall provide for thirty (30) days’ written notice to Fiagon
from the insurer in the event of any cancellation or termination of the policy and shall endeavor to notify Fiagon in the event of a modification of the policy; Distributor shall, upon written request, provide Fiagon with proof that such insurance
is in force; and 
 o. Adhere to all policies and procedures published by Fiagon NA for implementation of its distributor
relationships, unless such policies and procedures violate any terms of this Agreement. 
 4. Use of Trademarks and Trade Names.
Nothing in this Agreement shall be read as transferring ownership in any intellectual property belonging to any party. Fiagon NA grants Distributor limited permission during the Term of this Agreement to use the trademarks and trade names of Fiagon
and solely to (i) designate the source of a Product; (ii) identify Distributor as an authorized distributor of Fiagon NA or the Products, and (iii) subject to the limitation set forth below, promote, market and sell Products in the
Territory. Distributor’s use of the trademarks and trade names of Fiagon and Fiagon NA must comply with any reasonable usage guidelines provided in writing by Fiagon NA to Distributor. Distributor is required to secure prior written approval
from Fiagon NA before using the Fiagon® trademarks or Fiagon or Fiagon NA trade names on any advertising or promotional material. If, in Fiagon NA’s sole

  
 6 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
opinion, any proposed material contains a matter which may lessen the value of such trademark, Distributor agrees to delete or modify such matter to the satisfaction of Fiagon NA prior to
printing, distribution or use of such material. Distributor shall have the right to incorporate Entellus trademarks and tradenames in marketing materials alongside the trademarks and trade names of Fiagon. Fiagon agrees it will secure
Distributor’s prior written approval before distributing any marketing materials that includes Distributor’s trademarks and trade names. 

5. Confidential Information and Trade Secrets, Non-Disparagement and Injunctive Relief. 

a. Confidential Information and Trade Secrets. The parties acknowledge and agree that as a result of the relationship
established by this Agreement, they may obtain access to Confidential Information of the others. “Confidential Information” means any information disclosed by either Fiagon or the Distributor (each a “Disclosing Party”) to the
other party (each a “Recipient”) which relate directly or indirectly to the Disclosing Party’s products, services or business and which is disclosed in tangible or electronic form and clearly marked as “confidential” or
“proprietary” or bears a similar designation, is disclosed orally or otherwise in intangible form and identified as confidential at the time of disclosure followed within 30 days of disclosure by a written transmission containing a summary
of the disclosed information and confirming its confidential or proprietary nature, and/or should reasonably be understood to be confidential or proprietary given the nature of the disclosed information and/or the circumstances surrounding
disclosure. Confidential Information may include technology, ideas, concepts, drawings, designs, inventions, discoveries, improvements, patents, patent applications, specifications, trade secrets, prototypes, processes, notes, memoranda and reports,
or visual representations concerning the Disclosing Party’s past, present or future research, technology, know-how, and concepts, or computer programs, software code, written documentation, products, information concerning vendors, members,
customers, prospective customers, employees and prospective employees, market research, sales and marketing plans, distribution arrangements, financial statements, financial information, financing strategies and opportunities and business plans. A
Recipient shall keep Confidential Information of the Disclosing Party confidential and shall not disclose it to any unaffiliated third party or use it for any purpose other than to exercise its rights and fulfill its obligations under this Agreement
without the prior written consent of the Disclosing Party. The Recipient agrees to preserve the confidentiality of such information with at least the same degree of care as that taken by the Recipient to preserve and protect its own confidential or
proprietary information, and in no case less than a reasonable degree of care. The Recipient shall not be obligated to maintain any information in confidence, if: the information was lawfully in the Recipient’s possession or was known to it
prior to its disclosure from the Disclosing Party as evidenced by written records; the information is, at the time of disclosure, or thereafter becomes public knowledge without the fault of the Recipient; the information is or becomes rightfully
available on an unrestricted basis to the Recipient from a source other than the Disclosing Party which did not acquire the same under an obligation of confidentiality to the Disclosing Party; or the information becomes available on an unrestricted
basis to a third party from the 

  
 7 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
Disclosing Party or from someone acting under its control. Further, the Recipient may disclose the Disclosing Party’s Confidential Information if and to the extent disclosure is required by
subpoena or pursuant to a demand by any governmental authority, provided, however, that before such disclosure, the Recipient shall, to the extent permitted, notify the Disclosing Party of its intent to do so, and give the Disclosing Party
reasonable opportunity to take action to protect its rights and interest in such information. Neither party shall disclose the terms of this Agreement to an unaffiliated third party without the prior written approval of the other party, except for
legal, financial, accounting, or other similar advisors who have a need to know any of such terms and agrees to keep them confidential. The parties shall have the right to disclose the terms of this Agreement to current shareholders and in
connection with bona fide fund raising or sale of stock, provided that such disclosure is no broader than necessary to satisfy such purpose and is made under a confidentiality agreement including substantially similar confidentiality terms as
provided herein. 
 b. Non-Disparagement. The parties shall not, directly or indirectly, during the Term of this
Agreement or at any time thereafter, do or refrain from doing anything that may untruthfully disparage the reputation, prestige, value, image or impression of their respective trademarks or any other intellectual property of the party, the other
party, the Products, or any of the other party’s officers, directors, affiliates, personnel, products, brands, or related companies, by words, actions or other communications, or by any omissions to speak, act or otherwise communicate, or in
any other manner whatsoever. 
 c. The parties understand and acknowledge that any breach of Section 5a or 5b or certain
other breaches hereof may cause the non-breaching party irreparable harm, the amount of which may be difficult to ascertain, and therefore agrees that notwithstanding the provisions of Section 14 hereof, the non-breaching party shall have the
right to apply to a court of competent jurisdiction for specific performance and/or an order restraining and enjoining any such further breach and for such other relief as the non-breaching party shall deem appropriate. Such right of the
non-breaching party is to be in addition to the remedies otherwise available to the non-breaching party at law or in equity. The breaching party hereby expressly waives the defense that a remedy in damages will be adequate and any requirement in an
action for specific performance or injunction for the posting of a bond by the non-breaching party. 
 6. Terms and Conditions of
Sale. No order for Products is deemed made until accepted by Fiagon NA. The Terms and Conditions of Sale attached as Exhibit F, as modified from time to time by Fiagon NA upon reasonable notice to Distributor, shall govern all such
orders. Distributor acknowledges that these Terms and Conditions supersede any terms and conditions on any purchase order or other document supplied by Distributor to Fiagon NA. The parties shall separately establish, and Fiagon NA may from time to
time review and modify, the credit terms, if any, granted by Fiagon NA to Distributor. 

  
 8 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 7. Warranty and Limitation on Remedies; Disclaimer. 

a. Fiagon agrees to pass on to customers the warranties provided by Fiagon on the Products. The term “customer,” as
used herein, means the first end-user customer that purchases the Products and not any subsequent purchaser or user. Fiagon warrants that the Products will be free from defects in material and workmanship under normal use and service with proper
maintenance for eighteen (18) months. The term for such warranties shall begin upon receipt of a Product by the Distributor’s customers. In the event that Distributor has received a Product from Fiagon more than 180 days prior to its
shipment to the customer (the “Excess Period”), Distributor shall reimburse and indemnify Fiagon for all costs and expenses from warranty claims that occur within the time period equal to the Excess Period before the end of the eighteen
(18) months warranty period. For example, if Distributor ships a Product to a customer after holding it in its inventory for 181 days, then the Distributor shall reimburse and indemnify for any warranty claims that arise on the last day of the
18 month warranty period. In the event that Distributor uses the Product itself for demo or other purposes, it the term of the warranty to Distributor shall begin upon Distributor’s receipt of the Product. Products used by Distributor for
demonstration or other purposes may not be sold to customers or any other third parties without Fiagon’s express written consent. Distributor and customers shall promptly notify Fiagon of any known warranty claims and shall cooperate in the
investigation of such claims. If any Product is proven to not conform with this warranty during the applicable warranty period, Fiagon shall, at its exclusive option, either: repair, replace the Products, or refund the purchase price paid by
Distributor for each non-conforming Product, within a reasonable time after written notification of the non-conformity and return of the Product to Fiagon NA. Fiagon shall have no obligation under the warranty set forth above if the customer fails
to notify Fiagon in writing during the warranty period of a non-conformity. 
 b. Any modification by Distributor or a
customer of the Products or any use, misuse or neglect thereof by the customer in a manner inconsistent with the specifications or directions for use or maintenance of the Product shall void the warranty protection provided by Fiagon. Fiagon shall
NOT be held liable or assume any responsibility for products damaged by improper installation, handling or maintenance. 
 c.
Fiagon’s obligation in the event of a breach of warranty is limited to the remedies set forth in this Section 7. THE LIMITED WARRANTY SET FORTH ABOVE, OR ANY SUCCESSOR WARRANTY, IS IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, WHICH
ARE HEREBY DISCLAIMED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. 

d. In no event, be it for breach of warranty, breach of contract, negligence or any other cause of action shall Fiagon be
liable to Distributor or any customer for consequential, incidental or punitive damages even if such damages were reasonably foreseeable. 

e. Fiagon’s warranty and responsibility are limited to the Fiagon Products itself. Fiagon takes no responsibility for any
direct or indirect cost, losses or damages however incurred. 

  
 9 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 f. Returns must be accompanied by a return authorization number (RMA)
obtained from Fiagon Technical Support, and prepaid postage and insurance. 
 g. Fiagon products returned to Fiagon with an
RMA will be completed within 1-2 weeks of receipt of the product by Fiagon. 
 h. Fiagon reserves the right to make changes
or improvements in design or manufacturing without assuming any obligation to change or improve products previously manufactured. 

i. Fiagon does not make nor does it give the authority to any employee, agent or representative of Fiagon to make any other
warranties, or implied warranties, or to waive, alter, vary or add to the terms hereof without the prior written approval of an officer of Fiagon. 

8. Term and Termination. 

a. Unless sooner terminated by mutual agreement or because of an uncured breach hereof, the initial term of this Agreement
begins on the Effective Date and will continue until June 30, 2020 (“Initial Term”). The Agreement will automatically renew in successive 24 month periods thereafter unless either party provides to the other party written notice of
non-renewal at least 365 days prior to the end of the then-current term. The Initial Term and all renewal terms constitute the “Term” of this Agreement. 

b. This Agreement may be terminated on at least thirty (30) days prior written notice by either of the parties in the
event of a material breach by the other party of its obligations under this Agreement, provided the party intending to terminate the Agreement under this section provides the other party a detailed description of the claimed breach in the notice and
the breach remains uncured at the conclusion of the 30-day notice period. Notwithstanding anything to the contrary set forth above, either party may terminate this Agreement immediately upon written notice to the other if that other party
(i) engages in any act which materially impairs the goodwill associated with the Products or the trademarks of the terminating party; (ii) violates the provisions of Section 5 of this Agreement, (iii) ceases active operation of
its business, or (iv) engages in any materially unlawful conduct involving the manufacture, sale or distribution of the Products, whether such is subject to governmental action or not. 

c. Fiagon may terminate the Distribution Agreement on at least thirty (30) days prior written notice in the event the
Distributor does not meet the performance standards specified in Exhibit E. 
 d. This Agreement shall automatically
terminate if (i) a party files a bankruptcy petition or is the subject of an involuntary bankruptcy petition which is not dismissed within thirty (30) days, becomes insolvent, is subject to an arrangement with creditors, or has a receiver
or trustee appointed for its assets, or (ii) Fiagon NA is unable to continue to import Fiagon® surgical navigation systems. 

  
 10 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 e. Upon termination or non-renewal of this Agreement, Distributor will
immediately cease to represent itself as an authorized distributor of Fiagon or the Products, will immediately cease all use of trademarks or trade names of Fiagon, and will take all action reasonably possible to cause the removal of trademarks and
trade names from all signs, directories, business cards, sales literature, advertisements and any other places where Distributor has used these valuable assets; provided that unless this Agreement is terminated for Distributor’s breach or
Fiagon NA exercises its option under Section 8.e below, Distributor may, for a period of three (3) months from the termination date, continue to sell such remaining inventory of Products bearing Fiagon® trademarks on a non-exclusive basis as Distributor may have on the effective date of termination, so long as Distributor complies with the terms and conditions of this Agreement and all
applicable laws. 
 f. Upon termination or non-renewal, Fiagon NA may, in its sole discretion, repurchase from Distributor
all or any part of Distributor’s inventory of new, currently-supported Products that are in saleable condition at original purchase price from Fiagon NA. 

g. Distributor shall assist Fiagon and/or its designee in any reasonable manner, including the granting of access to offices of
Distributor at any reasonable time, in order to effect the smooth transition of the distribution to a different distributor and to ensure the continuity of the business of Fiagon and/or its designee after termination of this Agreement. 

h. Not later than thirty (30) days after the termination or expiration of this Agreement, Distributor shall render
adequate and final accountings to Fiagon with respect to any transaction as to which it has not yet rendered an accounting. 

i. In the event of termination or non-renewal of this Agreement for any reason, neither party shall owe any compensation to the
other party for lost profits, lost opportunities, goodwill, nor any other loss or damage as a result of or arising from such termination. Distributor acknowledges that it has not paid any consideration for the right to act as Fiagon’s
distributor in the Territory. 
 j. Termination of this Agreement for any reason shall not terminate those provisions which
by their terms are intended to be on-going including, without limitation, Sections 5, 7, 8, 11 and 14 hereof or any right to payment for Products. 

9. Relationship of the Parties. The relationship established between Fiagon and Distributor by this Agreement is that of a supplier to
its distributor. Distributor shall be solely responsible for all costs incurred by Distributor in connection with sale of the Products, including facility, employee, travel, tax and employee costs, except that Fiagon shall be solely responsible for
all taxes typically assessed on the manufacturer or importer of the Products (including the Medical Device Excise Tax). Distributor shall be entitled to price the Products as it sees fit. While Fiagon has an interest in the ultimate result of
Distributor’s sales efforts, it shall 

  
 11 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 
not dictate the specific manner in which Distributor conducts its day-to-day affairs. Distributor is not an agent, partner, joint venturer or franchisee of Fiagon. Distributor has no authority to
bind Fiagon, transact any business in Fiagon’s name or on its behalf in any manner, or make any promises or representations on behalf of Fiagon. The employees and agents of Distributor are not for any purpose the employees or agents of Fiagon,
nor are employees and agents of Fiagon the employees or agents of Distributor for any purpose. 
 10. Force Majeure. Neither party
will be liable for any failure to perform its obligations under this Agreement, if due to any cause beyond the reasonable control of the non-performing party including, without limitation, natural disasters, war, strikes, import restrictions, or
legal or regulatory prohibitions. 
 11. Indemnification. 

a. Distributor will indemnify, defend, and hold Fiagon and its parents, affiliates and their respective officers, directors and
representatives (collectively, “Fiagon Indemnitees”) harmless from any claims, costs, suits or damages (including reasonable attorneys’ fees and court costs) made or brought against Fiagon as a result of a breach by Distributor of any
of the terms of this Agreement. 
 b. Fiagon will indemnify, defend, and hold Distributor and its parents, affiliates and
their respective officers, directors and representatives (collectively, “Distributor Indemnitees”) harmless from any claims, costs, suits or damages (including reasonable attorneys’ fees and court costs) made or brought against
Distributor as a result of a breach by Fiagon of any of the terms of this Agreement. 
 c. The Parties hereby agree that they
will cooperate in the defense of any [***] claims brought against them based on the sale or use of the Products within the Territory. It is the Parties intent that the costs of such claims shall be borne by the Party whose products gave rise to the
claims. Towards that end, Entellus and Fiagon agree that: 
 i) Fiagon shall indemnify, defend, and hold Distributor
Indemnitees harmless from any costs or damages (including reasonable attorneys’ fees and court costs) arising from a claim that a product [***]. 

ii) Distributor shall indemnify, defend, and hold Fiagon Indemnitees harmless from any costs or damages (including reasonable
attorneys’ fees and court costs) arising from a claim that a product [***]. 
 iii) For any [***], then the Parties
agree to indemnify, defend, and hold the other harmless from the portion of any costs or damages (including reasonable attorneys’ fees and court costs) that are attributable to [***]. That is, Fiagon shall indemnify Distributor for [***].
Distributor and Fiagon agree they will share equally any costs or damages (including reasonable attorneys’ fees and court costs) that are not reasonably apportionable to [***]. 

  
 12 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 d. A party seeking indemnification (an “Indemnified Party”) shall
give the other party (an “Indemnifying Party”) written notice of any third party claims covered by Section 11.a, 11.b, or 11c above within ten (10) days of first knowledge thereof. The Indemnifying Party shall have sole and
exclusive control of the defense of any legal action, including the choice and direction of legal counsel, and the Indemnified Party shall fully cooperate in the defense thereof. 

12. Assignment. This Agreement will inure to the benefit of and be binding upon the permitted successors and assigns of the parties
hereto. Distributor may not assign or transfer this Agreement or any right or obligation arising under it to any other party without the prior written consent of Fiagon NA, which consent shall not be unreasonably denied if the proposed assignee
establishes the intent and wherewithal to fulfill the Distributor’s duties hereunder to the satisfaction of Fiagon. A merger, sale of a majority of the legal or beneficial interests in the shares of the Distributor or a sale of substantially
all the assets shall be deemed an assignment. 
 13. Fiagon shall provide Distributor at least ten (10) days written notice before
Fiagon begins any process to merge with a third party, sell a majority of the legal or beneficial interest in the shares of Fiagon or to sell substantially all of its assets to any third party. 

14. Notices. All notices must be in writing and will be deemed to have been given (i) when delivered in person, delivered by
internationally-recognized overnight courier or (ii) two (2) days after delivery by facsimile transmission or email if a copy of the facsimile or email is placed in the mail the same day, addressed to such party as set forth below or as
may hereafter be specified in writing in accordance with this Section 13: 
  

			
	Fiagon NA:	  	Fiagon NA
		  	3913 Todd Lane #101
		  	Austin, TX 78744
		  	Facsimile: +49 3302 201 21 15
		  	Email: info@fiagon.com
		
	Distributor:	  	Entellus Medical
		  	Chief Executive Officer
		  	3600 Holly Lane North, Suite 40
		  	Plymouth, MN 55447
		  	Facsimile: 763-463-1599
		  	Email: bwhite@entellusmedical.com

 15. Forum Selection; Controlling Law. This Agreement is deemed to have been made in the State of New
York, USA and shall be governed by and interpreted pursuant to New York law. Any disputes arising out of this Agreement or the relationship of the parties hereto shall be litigated exclusively in the state or federal courts of the State of New York,
USA. All parties consent to the jurisdiction of New York courts and waive any defense of forum-non-conveniens. This Agreement shall not be subject to the United Nations Convention for the International Sale of Goods. 

  
 13 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 16. Attorneys’ Fees. The prevailing party shall be entitled to recovery of costs,
including reasonable attorneys’ fees, in any legal action brought in connection with this Agreement. 
 17. Entire Agreement.
This Agreement, including the Exhibits attached hereto, represents the entire understanding of the parties with respect to its subject matter. It incorporates all prior negotiations, representations, and understandings, whether written or oral, with
regard to the relationship between Fiagon and Distributor. No supplement, modification, or other change may be made to any of the terms of this Agreement unless contained in a written document signed by both parties. 

18. Counterparts and Faxed Signatures. This Agreement may be executed in any number of counterparts by the parties hereto or in
separate counterparts, each of which when so executed shall be deemed to be an original and all of which together shall constitute one and the same Agreement. A faxed or emailed signature shall be sufficient to bind a party hereto. 

19. Authority. Each party represents that it has the authority to enter into this Agreement and that it constitutes a binding
commitment of the party. 
 IN WITNESS WHEREOF, the undersigned have set their hands, intending to be bound hereby. 

 

									
		 		 		 	FIAGON NA CORPORATION
					
	Dated:  	 	 8-10-15
	 		 	By	 	 /s/ Timo Kruger

		 		 		 	Its	 	 VICE PRESIDENT

				
		 		 		 	DISTRIBUTOR:
					
	Dated:	 	 8-10-15
	 		 	By	 	 /s/ Robert S. White

		 		 		 	Its	 	 PRESIDENT & CEO

  
 14 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 EXHIBIT A 

PRODUCTS 
 Distributor will be
entitled to purchase from Fiagon NA the following surgical navigation systems and components, parts and ancillary products related thereto, including future upgrades and additions to the product line related to Ear Nose & Throat
(“Products”). Fiagon reserves the right to upgrade, modify and supplement its Products: 

  
 A-1 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

  
 

 

  
 A-2 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

  
 EXHIBIT B 

TERRITORY 
 Unless hereafter
modified by mutual written agreement or as a condition of renewal of the Term, Distributor’s Territory consists of the following geographical area: 

Territory includes the continental United States of America, Hawaii, Alaska, Puerto Rico, the U.S. Virgin Islands, and any other territories or possessions
held by the United States of America as of the Effective Date. 

  
 B-1 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 EXHIBIT C 

INITIAL DISTRIBUTOR PRICING 
 The
current Distributor Pricing (also referred to herein as the “Transfer Price” or “Transfer Pricing”) for the Products is either described below or in a price list that will be delivered to Distributor: 

[***] 

  
 C-1 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

  
 EXHIBIT D 

REQUIREMENTS FOR ACQUIRING AND 

MAINTAINING EXPERTISE IN CAPABILITIES, 

USE AND SUPPORT OF FIAGON® PRODUCTS 

The following are the mutually agreed expectations with regard to the development and maintenance by Distributor of internal expertise on Fiagon® Products so as to be able to support the efforts of other Distributor employees in the sales and support of the Products: 

Fiagon agrees to work with Distributor to develop future products in joint effort. [***] 

  
 F-1 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 EXHIBIT E 

INITIAL PERFORMANCE STANDARDS 

Unless otherwise agreed, Distributor is expected to purchase no less than the following dollar volume (or, if applicable, type) of Products during the
following contract years: 
 Contract Year 1 (i.e., August 10, 2015 – August 9, 2016): [***] Fiagon Navigation Systems 

Contract Year 2 (i.e., August 10, 2016 – August 9, 2017): [***] Fiagon Navigation Systems 

Contract Year 3 (i.e., August 10, 2017 – August 9, 2018): [***] Fiagon Navigation Systems 

Contract Year 4 (i.e., August 10, 2018 – August 9, 2019): [***] Fiagon Navigation Systems 

Contract Year 5 (i.e., August 10, 2019 – August 9, 2020): [***] Fiagon Navigation Systems 

The Distributor shall provide Fiagon more detailed and specific forecasts of its expected purchases in accordance with Section 3, but such forecasts
shall respect the above mentioned system purchase expectations. 
 During the Term of this Agreement, Distributor is expected to purchase [***] of
disposable and accessory items (not counting service contract revenue) during each of the first five 12-month periods following the order of a Fiagon Navigation System by Entellus, for a total of [***] in disposable and accessory items over the
course of five contract years for each ordered Fiagon Navigation System. 
 Further, Distributor is expected to purchase an additional [***] of disposable
and accessory items (not counting service contract revenue) during the first 12-month period following the Effective Date and [***] of disposable and accessory items (not counting service contract revenue) during the 2nd, 3rd, 4th, and 5th 12-month period
following the Effective Date. 
 Should the Distributor’s Product purchases exceed the above-prescribed Product purchase expectations for one of the
prescribed time periods, then those surplus purchases shall be applied towards the purchase expectations of subsequent time periods. 
 Should Distributor
fail to meet the above-prescribed performance standards, then Fiagon’s sole remedy hereunder shall be: i) an option in its sole discretion to immediately replace all or part of the exclusive distribution rights granted to Distributor in
Section 1(a)(i) in favor of a non-exclusive distribution right or ii) terminate this Agreement per the terms in Section 8c. 

  
 F-2 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 EXHIBIT F 

STANDARD TERMS AND CONDITIONS 

FOR SALES OF PRODUCTS 

1. Orders. Distributor will place orders for Products in the manner described in Fiagon NA’s distributor policies and procedures.
No order is deemed placed until accepted in writing by Fiagon NA. The terms of the Distributor Agreement shall apply to all orders. Fiagon NA will make good faith efforts to fulfill orders by the estimated ship date established at the time the order
was placed but that date is an estimate and Fiagon NA cannot guarantee that it will be met. Furthermore, if Distributor’s order volume materially departs from its forecast volume, fulfillment of some of Distributor’s orders may have to be
delayed in order to enable Fiagon NA to fill orders of distributors whose order volumes are consistent with their forecasts. 
 2.
Delivery. Unless otherwise agreed in writing, each purchase is FOB Fiagon NA’s facility in Austin, Texas, USA. Distributor is solely responsible for causing the Products to be delivered to the location requested in the accepted order.
All risks of loss or damage during transport from Fiagon NA’s facility to Distributor rest with Distributor. Distributor should promptly inspect the Products upon receipt. If Fiagon NA is not informed of any non-conformity with
Distributor’s order within ten (10) calendar days of receipt, the Products contained in that delivered order are deemed to have been accepted by Distributor. 

3. Taxes. Distributor is exclusively responsible for, and shall pay all sales, use, or other taxes or duties related to the sales of
Products to Distributor or to the delivery of the Products into Distributor’s territory, while Fiagon is exclusively responsible for, and shall pay, all taxes levied on manufacturers or importers of the Products including the Medical Device
Excise Tax. 
 4. Payment Terms; Title. Payment terms on the Products shall be Net 30. Distributor shall not be entitled to withhold
any payment due to Fiagon by way of set-off or counter-claim. Fiagon NA is authorized to file financing statements to provide notice that it retains an interest in Products for which Distributor has not paid in full. If Distributor fails to pay for
Products within the time provided in its credit arrangement with Fiagon NA, is the subject of a voluntary or involuntary bankruptcy petition, or is reasonably deemed to be insolvent, Fiagon NA shall be entitled to secure possession of the Products
for which it is still owed money and Distributor shall cooperate in the delivery of that possession. 
 5. Late Payment. Unless
otherwise provided in a credit agreement between the parties, Fiagon NA shall be entitled to apply finance charges at the rate of 1.5% per month on the overdue balance or such lower rate as may be required by law. Distributor shall pay all
costs, including reasonable attorneys’ fees, incurred by Fiagon NA in any litigation to collect what is owed to it. 
 6.
Warranty. Distributor, and Distributor’s customers, shall receive the warranty applicable to the Products purchased from Fiagon NA as set forth in Section 7 of the Distributor Agreement. The limitation of liability provisions of the
Distributor Agreement apply to all Product orders. 
 7. Force Majeure. As provided in the Distributor Agreement, Fiagon NA is not
responsible for any delays caused by acts of God, war, strikes, computer failure, or other actions beyond its reasonable control. 
 8.
Exclusive Terms. These Standard Terms and Conditions, along with the Distributor Agreement, contain the exclusive agreement with respect to all orders for, and sales of Products and controls over any purported terms to which Fiagon NA has not
agreed in writing. 
 9. Forum Selection. Any dispute arising from, or relating to a Product order or shipment shall be exclusively
resolved in the federal and state courts of the State of New York, USA, and both parties consent to the jurisdiction of such courts. 

  
 F-3 

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 Exhibit G 

List of the other distribution agreements that grant a third person or entity rights to distribute a Fiagon branded product to ENT physicians in offices,
clinics, and surgery centers located within the Territory and the dates that such distribution rights are reasonably projected to expire: 
  

	 	1.	[***] shall have the right to sell Fiagon branded products to the following [***] ENT accounts: 

[***] 
  

	 	2.	[***] shall have the right to sell Fiagon branded products to [***]. 

  

	 	3.	[***] shall have the right to sell Fiagon branded products to the following [***] ENT accounts: 

[***] 
 Fiagon warrants that these limited
distribution rights for these other distributors shall expire no later than [***]. 

  
 F-4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}]]